High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Phase 1 Completed 10 enrolled The New York Eye Cancer Center Genentech, Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.

Timeline

Start: 2011-05
Primary completion: 2012-11
Completion: 2012-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ranibizumab	Monoclonal antibody	2 mg	Intravitreal

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Summary

Timeline

Drugs

Indications